Home › Mantle Cell Lymphoma › Pennsylvania › Philadelphia
Mantle Cell Lymphoma clinical trials in Philadelphia, PA
5 studies for Mantle Cell Lymphoma are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- University of Pennsylvania Abramson Cancer Center, Philadelphia
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
- Research Site, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
SynKIR-310 for Relapsed/Refractory B-NHL
RecruitingPhase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Philadelphia
Mantle Cell Lymphoma trials in other cities
- Houston, TX15 studies
- Baldwin Park, CA15 studies
- Durham, NC13 studies
- New York City, NY12 studies
- Seattle, WA12 studies
- Milwaukee, WI12 studies
- Boston, MA11 studies
- Nashville, TN11 studies
- Columbus, OH11 studies
- Chicago, IL10 studies
- Rochester, MN9 studies
- Portland, OR9 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.